Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Hi Van2000, big pharma acquire small biotech companies all the time. Recent examples include GSK's acquisition of Affinax for $2.1 billion. Affinax had a pneumococcal virus vaccine in phase 2 trials; Astrazenecca's acquisition of Cincor for $1.3 billion for a drug for treating hypertension and kidney disease; Merck's acquisition of Prometheus Bioscience for $10.8 billion for a phase 2 bowel disease drug; and Pfizer's acquisition of Seagen for a staggering $43 billion for a cancer treatment. The big pharma companies are clearly willing to pay big bucks for the right drugs, even at phase 2 clinical trial stage in some cases.
Whilst the consensus view is that xf-73 will find a big pharma to take it through phase 3 trials there is always the possibility of course that big pharma will make an offer for xf-73 outright to have full control. What would big pharma be willing to pay for a drug which would potentially generate billions per year in revenue? Many big pharma companies are awash with cash at the moment and willing to pay very large cheques to bolster their pipelines of assets ahead of expiring patents.
Many thanks for your detailed notes once again Wally. I did actually listen to the presentation but it's great to get a recap. I was slightly concerned when Monday's RNS came out about the lack of efficacy data but it makes sense now as there is plethora of data to analyse judging by the presentation slide. Plenty to look forward to in 2023 and I see a gradual climb to previous highs and beyond early next year.
DesertStar, I've just noticed JS has put out a video this morning which seems go some way to reassuring me that all us still well (look at polb twitter). In the video he states that although safety of polb001 was already demonstrated it has now additionally been demonstrated in an inflammatory setting was was important to prove. He stresses also several times that the detailed data analysis is essential in attracting big pharma next year, so perhaps it would be premature to make a hasty analysis of the results just for the sake of appeasing shareholders in what I suppose is not a totally binary outcome. I do feel more confident having listened to the interview as his body language and enthusiam for striking a good deal are both very positive.
Looking back at the interim results RNS in Sep it states that initial results from the trial are expected before the end of 2022. The big question therefore is what do initial results mean. I, like most shareholders assumed initial efficacy data. If it meant only safety data it was not clearly stated hence the sense that we have been mislead somewhat. Safety was never really going to be an issue as polb001 has already been demonstrated to be safe. I do find it slightly concerning that there is no mention of efficacy at this stage. Does it really take 4 months to determine whether polb001 blocks inflammation? Some initial read out and interpretation of the results could surely be made.
Commercialisation takes time, particularly in the medtech industry because it's such a regulated one, but rest assured it is happening. View the interim results analyst meeting. It will give you all the detail you need to be confident that progress is happening. The share price decline is reflective of the bear market generally, not an operational one.
It's very difficult to accurately predict what sort of revenues Angle will generate in the future. What we know for sure is that Angle has a multi-pronged and layered commercialisation strategy which is potentially worth billions. It has a cash runway of at least two years, is currently revenue generating from pharma services and with a substantial pipeline of other pharma companies and medtech companies in discussions with, and uniquely placed in the liquid biopsy market as being the only company worldwide to have an FDA cleared product for the harvesting of CTCs for analysis.
https://webcast.openbriefing.com/angle-sep22/player/?player_id=49448
You can count on it Simon that Gerry will have done his sums.
Skinara appear to have a very different business model to STC. With Skinara you pay for the test kit upfront and then based on your skin microbiome are recommended Skinara-only products. They will incur marketing costs in order to sell the kit, and will then be limited to selling only their own products which limits their global reach.
With STC the kits are given away for free and then the products of STC's clients (i.e dozens of Tier 1 skin care companies) are sold to STC members on a revenue share basis, with enormous global reach. STC won't have the marketing costs because the microbiome data will effectively sell the product. Also STC will have the benefit of having built up many years of that data which can then be used to market more products in many other ways. This model is what sets STC apart from any other skin microbiome company.
The reach for STC is staggering when you consider for example the loyalty card system. Skin care companies have millions of customers who have loyalty cards which at the moment essentially gives them access to information about previous purchases and lifestyle choices. How many loyalty card holders would rather have products recommended based on their skin type? Most of them you would think. Hence each loyalty card holder then becomes a potential STC member. And STC has dozens of clients with millions of loyalty card holders. All of a sudden you see the potential for STC. And then there is the medical, scalp etc sides to the business also which have barely begun.
The potential is truly massive.
Usual scaremongering nonsense by the odious TW. If I were him I'd be more concerned about the missing 100 grand.
You're treading on thin ice Shorty. Ever heard of libel. I suspect GB has much deeper pockets than you. You've been warned.
Very positive RNS. The £19m cash suggests an EV of currently £6m which is ridiculously low given the potential within the portfolio, including an immunomodulator potential blockbuster for treating severe influenza and other indications, currently in phase 2 HC trials.
It will be interesting to know what plans Gerry has for STC. As the bottleneck seems to be in the actual processing of home-test kits due to lab space I would like to think posssibly a JV with Tier one skincare company which has the required lab capacity on a revenue share basis to enable further expansion of STC. The STC business model clearly has huge potential as shown by the rapid expansion in the US and should be rolled out worldwide. This I understand was the intention when they brought in Media Monks who have reach across about 60 countries.
Shorteverything, can we have your 13.12 post in English please?